EXHIBIT 99.1



Contact:  Robert F. Laverty                       John Elicker
          Corporate Affairs                       Investor Relations
          (609) 252-5732                          (212) 546-3775
          bob.laverty@bms.com                     john.elicker@bms.com

                                                  Susan Walser
                                                  Investor Relations
                                                  (212) 546-4631
                                                  susan.walser@bms.com


          BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES THE EXPECTED TIMING
                    FOR FILING ITS THIRD QUARTER 2002 10-Q


NEW YORK, N.Y. (November 15, 2002) -- Bristol-Myers Squibb Company (NYSE:BMY)
today announced that it expects to file its third quarter 2002 10-Q in
February 2003. The company previously announced that there will be a delay in
filing the company's third quarter 2002 10-Q due to the expected restatement
of the company's sales and earnings. The restatement relates to the prior
periods that were affected, primarily in 2000, 2001 and the first two quarters
of 2002, by the company's previously disclosed U.S. wholesaler inventory
buildup situation. The company expects that there will be no delay in filing
of its 2002 10-K, which is due on March 31, 2003, and that it will amend
earlier filings at approximately the same time as it files its third quarter
2002 10-Q and, in any event, prior to filing its 2002 10-K.

                                      ###

This press release includes certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 regarding,
among other things, statements relating to goals, plans and projections
regarding the company's financial position, results of operations, market
position, product development and business strategy. These statements may be
identified by the fact that they use words such as "expect," and other words
and terms of similar meaning. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties, including
factors that could delay, divert or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. These
factors

                                   - more -





                                     - 2 -

include, among other things, changes to wholesaler inventory levels, the
results of the planned financial statement restatement process and the audit
of such restated financial statements and the impact and result of any
litigation or governmental investigations related to the financial statement
restatement process. For further details and a discussion of these and other
risks and uncertainties, see the company's Securities and Exchange Commission
filings. The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.